No Heading
Purpose.
Metformin, an antihyperglycemic agent, is eliminated by tubular secretion in addition to glomerular filtration in the human kidney. This study was performed to characterize metformin transport by human organic cation transporter 2 (hOCT2), the most abundant organic cation transporter in the basolateral membranes of the human kidney.
Methods.
Accumulation of [14C]metformin was assessed by the tracer experiments in the human embryonic kidney (HEK293) cells expressing hOCT2.
Results.
The transport of [14C]metformin was markedly stimulated in hOCT2-expressing cells compared with the vector-transfected cells. The accumulation of [14C]metformin was concentrative and was dependent on the membrane potential, showing consistency with the characteristics of hOCT2. The apparent Km and Vmax values of [14C]metformin transport by hOCT2-expressing HEK293 cells were 1.38 ± 0.21 mM and 11.9 ± 1.5 nmol mg protein−1 min−1, respectively. The order of the potencies of unlabeled biguanides to inhibit [14C]metformin transport by hOCT2 was phenformin > buformin > metformin. Furthermore, [14C]metformin transport was inhibited slightly or moderately by cationic drugs such as procainamide and quinidine at respective therapeutic concentrations.
Conclusions.
Metformin is transported by the basolateral organic cation transporter hOCT2 in the human kidney. hOCT2 could play a role in the drug interactions between metformin and some cationic drugs.
Similar content being viewed by others
Abbreviations
- hOCT1:
-
human organic cation transporter 1
- hOCT2:
-
human organic cation transporter 2
- rOCT1:
-
rat organic cation transporter 1
- HEPES:
-
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
References
1. P. Marchetti, R. Giannarelli, A. di Carlo, and R. Navalesi. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clin. Pharmacokinet. 21:308–317 (1991).
2. T. B. Klepser and M. W. Kelly. Metformin hydrochloride: An antihyperglycemic agent. Am. J. Health Syst. Pharm. 54:893–903 (1997).
3. I. W. Campbell. Metformin and the sulphonylureas: The comparative risk. Horm. Metab. Res. Suppl. 15:105–111 (1985).
4. C. R. Sirtori, G. Franceschini, M. Galli-Kienle, G. Cighetti, G. Galli, A. Bondioli, and F. Conti. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin. Pharmacol. Ther. 24:683–693 (1978).
5. P. J. Pentika;auinen, P. J. Neuvonen, and A. Penttila;au. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. 16:195–202 (1979).
6. A. Somogyi and M. Muirhead. Pharmacokinetic interactions of cimetidine 1987. Clin. Pharmacokinet. 12:321–366 (1987).
7. A. Somogyi, C. Stockley, J. Keal, P. Rolan, and F. Bochner. Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol. 23:545–551 (1987).
8. V. Gorboulev, J. C. Ulzheimer, A. Akhoundova, I. Ulzheimer-Teuber, U. Karbach, S. Quester, C. Baumann, F. Lang, A. E. Busch, and H. Koepsell. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16:871–881 (1997).
9. L. Zhang, M. J. Dresser, A. T. Gray, S. C. Yost, S. Terashita, and K. M. Giacomini. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51:913–921 (1997).
10. H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, M. Goto, A. Fukatsu, O. Ogawa, and K. Inui. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13:866–874 (2002).
11. Y. Urakami, M. Okuda, S. Masuda, H. Saito, and K. Inui. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J. Pharmacol. Exp. Ther. 287:800–805 (1998).
12. Y. Urakami, M. Okuda, S. Masuda, M. Akazawa, H. Saito, and K. Inui. Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm. Res. 18:1528–1534 (2001).
13. Y. Urakami, M. Akazawa, H. Saito, M. Okuda, and K. Inui. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13:1703–1710 (2002).
14. D. S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel, and Y. Sugiyama. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302:510–515 (2002).
15. D. S. Wang, H. Kusuhara, Y. Kato, J. W. Jonker, A. H. Schinkel, and Y. Sugiyama. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol. 63:844–848 (2003).
16. M. J. Dresser, G. Xiao, M. K. Leabman, A. T. Gray, and K. M. Giacomini. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm. Res. 19:1244–1247 (2002).
17. Y. Urakami, N. Kimura, M. Okuda, and K. Inui. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm. Res. 21:976–981 (2004).
18. M. M. Bradford. A Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248–254 (1976).
19. M. Okuda, H. Saito, Y. Urakami, M. Takano, and K. Inui. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun. 224:500–507 (1996).
20. N. C. Sambol, J. Chiang, M. O’Conner, C. Y. Liu, E. T. Lin, A. M. Goodman, L. Z. Benet, and J. H. Karam. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J. Clin. Pharmacol. 36:1012–1021 (1996).
21. A. J. Scheen. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 30:359–371 (1996).
22. M. B. Davidson and A. L. Peters. An overview of metformin in the treatment of type 2 diabetes mellitus. Am. J. Med. 102:99–110 (1997).
23. N. C. Sambol, J. Chiang, E. T. Lin, A. M. Goodman, C. Y. Liu, L. Z. Benet, and M. G. Cogan. Kidney function and age are both predictors of pharmacokinetics of metformin. J. Clin. Pharmacol. 35:1094–1102 (1995).
24. T. Katsura, M. Takano, Y. Tomita, M. Yasuhara, K. Inui, and R. Hori. Characteristics of organic cation transporter in rat renal basolateral membrane. Biochim. Biophys. Acta 1146:197–202 (1993).
25. A. Somogyi, A. McLean, and B. Heinzow. Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs. Eur. J. Clin. Pharmacol. 25:339–345 (1983).
26. R. Larsson, G. Bodemar, and B. Norlander. Oral absorption of cimetidine and its clearance in patients with renal failure. Eur. J. Clin. Pharmacol. 15:153–157 (1979).
27. P. A. Bjaeldager, J. B. Jensen, N. E. Larsen, and E. F. Hvidberg. Elimination of oral cimetidine in chronic renal failure and during haemodialysis. Br. J. Clin. Pharmacol. 9:585–592 (1980).
28. A. Somogyi, H. G. Rohner, and R. Gugler. Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin. Pharmacokinet. 5:84–94 (1980).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kimura, N., Okuda, M. & Inui, Ki. Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2. Pharm Res 22, 255–259 (2005). https://doi.org/10.1007/s11095-004-1193-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-004-1193-3